376930.Kq

The company's capital structure is characterized by a debt-to-equity ratio of 0.28, indicating a relatively low reliance on debt financing compared to equity. However, the liquidity position is assessed as medium, with a current ratio of 3.91, suggesting the company has sufficient short-term assets to cover its liabilities, but with limited excess liquidity. The company's cash and equivalents amount to 656,290,180 KRW, which is significantly lower than its long-term debt of 7,121,291,240 KRW, resulting in a net cash position that is negative after subtracting total debt.

Profitability metrics are severely negative, with a return on equity of -0.777 and a return on assets of -0.5087, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are well below the typical performance of the biotechnology and medical research industry, where positive returns are expected for long-term sustainability.

The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no additional geographic or product diversification provided in the available data. This lack of diversification increases the company's exposure to market-specific and operational risks, as any downturn in its primary business could significantly impact its financial performance.

The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating and net losses of 20,089,801,870 KRW and 19,954,848,720 KRW, respectively, suggest that the company is not currently generating positive earnings and may require significant capital to sustain operations. The negative operating and free cash flows of -20,531,114,400 KRW and -20,657,946,810 KRW, respectively, further indicate that the company is not generating sufficient cash from its operations to fund its capital expenditures of -2,879,669,090 KRW.

The risk assessment highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for its long-term debt. The dilution risk is assessed as low, with no significant dilution potential identified in the available data. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to share dilution.

Recent events and filings do not provide specific details on the company's strategic initiatives or financial developments. The absence of detailed information on recent business activities or financial disclosures limits the ability to assess the company's current strategic direction and operational performance.